588 Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC) in the RUBY trial: post hoc analysis of the costs of grade ≥3 adverse events (AEs)
oleh: Llenalia Garcia-Fernandez, Jean Hurteau, Lydia Lee, Solomon J Lubinga, Tilman Payer, Meghann Gregg, Odette Allonby
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2023-11-01 |
Deskripsi
No description available for this item.